{"id":"W2891568037","doi":"10.1200/jco.2017.35.15_suppl.10524","title":"A phase I/II study of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors (iMATRIX-Atezolizumab).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Ependymoma; Refractory (planetary science); Internal medicine; Sarcoma; Gastroenterology; Oncology; Cancer; Surgery; Pathology; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001495634,0.0007928315,0.001223714,0.0002151212,0.000280215,0.0005240623,0.0004188045,0.0006756964,0.002775605],"category_scores_gemma":[0.0007504127,0.0004417597,0.0008036026,0.000292776,0.0004862869,0.0004310696,0.0002768568,0.001667179,0.0008509767],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006363998,"about_ca_system_score_gemma":0.00159121,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009012313,"about_ca_topic_score_gemma":0.002396189,"domain_scores_codex":[0.9997008,0.0001266502,0.00002139332,0.00006050205,0.00003397368,0.00005664632],"domain_scores_gemma":[0.9993646,0.00005980387,0.0001268616,0.00004460679,0.00005199488,0.0003522489],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5494474,0.1093675,0.08178534,0.001174329,0.002165121,0.001229203,0.0008096353,0.00218314,0.07481226,0.0004599597,0.0122793,0.1642867],"study_design_scores_gemma":[0.4362739,0.4678851,0.07808948,0.0000613983,0.0006320651,0.001614781,0.0001857357,0.001115595,0.004407187,0.0001905133,0.009513096,0.00003113655],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920403,0.001965992,0.000434575,0.0002792938,0.00008699128,0.002472688,0.001575911,0.00004957455,0.001094577],"genre_scores_gemma":[0.9809775,0.002825148,0.002860145,0.001394191,0.0001660285,0.003873577,0.005486762,0.00002700609,0.002389639],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002775605,"threshold_uncertainty_score":0.009285331,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07854338184453231,"score_gpt":0.4758854040754624,"score_spread":0.3973420222309301,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}